KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Non-Current Debt (2016 - 2022)

Pacific Biosciences Of California has reported Non-Current Debt over the past 12 years, most recently at $500000.0 for Q4 2022.

  • For Q4 2022, Non-Current Debt fell 78.26% year-over-year to $500000.0; the TTM value through Dec 2022 reached $500000.0, down 78.26%, while the annual FY2022 figure was $500000.0, 78.26% down from the prior year.
  • Non-Current Debt for Q4 2022 was $500000.0 at Pacific Biosciences Of California, down from $2.3 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $15.8 million in Q4 2019 and troughed at $500000.0 in Q4 2022.
  • A 4-year average of $10.8 million and a median of $14.1 million in 2018 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 37.57% in 2018 and later tumbled 78.26% in 2022.
  • Year by year, Non-Current Debt stood at $14.7 million in 2018, then rose by 7.78% to $15.8 million in 2019, then crashed by 85.44% to $2.3 million in 2021, then tumbled by 78.26% to $500000.0 in 2022.
  • Business Quant data shows Non-Current Debt for PACB at $500000.0 in Q4 2022, $2.3 million in Q4 2021, and $15.8 million in Q4 2019.